Revenue: As of FY2025 Q2, the actual value is USD 200.68 K.EPS: As of FY2025 Q2, the actual value is USD -1.17.<h3>Biotechnology Segment</h3><ul><li>Net Loss from Operations: The biotechnology segment reported a net loss from operations of $4,413,385 for the three months ended June 30, 2025, and $8,428,087 for the six months ended June 30, 2025.</li><li>Total Operating Expenses: Total operating expenses for the biotechnology segment were $4,413,385 for the three months ended June 30, 2025, and $8,428,087 for the six months ended June 30, 2025.</li></ul><h3>Technology Segment</h3><ul><li>Sales: The technology segment generated sales of $200,681 for the three months ended June 30, 2025, and $263,555 for the six months ended June 30, 2025.</li><li>Cost of Goods Sold: The cost of goods sold for the technology segment was $45,157 for the three months ended June 30, 2025, and $90,313 for the six months ended June 30, 2025.</li><li>Net Loss from Operations: The technology segment reported a net loss from operations of $107,829 for the three months ended June 30, 2025, and $150,111 for the six months ended June 30, 2025.</li><li>Total Operating Expenses: Total operating expenses for the technology segment were $263,353 for the three months ended June 30, 2025, and $323,353 for the six months ended June 30, 2025.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: The company reported net cash used in operating activities of -$4,762,909 for the six months ended June 30, 2025.</li><li>Net Cash Provided by Financing Activities: The company reported net cash provided by financing activities of $6,226,750 for the six months ended June 30, 2025.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to continue focusing on the development of its biotechnology product pipeline and enhancing its technology segment through advanced technologies. The biotechnology segment is expected to remain non-revenue generating while the technology segment continues to generate revenue through its NexGenAI Affiliates Network platform.</li><li>Non-Core Business: The company is considering strategic partnerships for the development of its GEAR and SNAP-CAR platforms and is in negotiations to divest its remaining ownership rights in CPT60621.</li></ul>

Coeptis Therapeutics - CW25 | 10-Q: FY2025 Q2 Revenue: USD 200.68 K